Drugs / SRSD384
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07557355 | Jun 2026 → Oct 2027 expected | obesity disorder | Sirius Therapeutics Co., Ltd. | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SRSD384 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07557355 ↗ |
| Route | Subcutaneous | “Administered S.C. per the protocol” NCT07557355 ↗ |